Novita Pharmaceuticals
- Biotech or pharma, therapeutic R&D
Novita has a Fascin Inhibitor, NP-G2-044, which is a first-in-class, novel MOA that acts to inhibit metastasis and modulate immune function of Dendritic Cells resulting in synergy with PD-1 inhibitors, in almost all solid tumors. Phase 2 set to complete this summer, phase 3 (ULTIMUS1) FPI in July. ULTIMUS1 is a phase 3 in PROC in combination with PLD.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}